Company Overview
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical entity focused on developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction within Israel. The company is situated within the Healthcare sector, specifically the Biotechnology industry, which implies a focus on early-stage research and development rather than mature commercialization. The firm's total market capitalization stands at $6.89M, while its annual revenue for the trailing twelve months was recorded at $405,000. The employee count is listed as N/A, indicating that the specific headcount data is not disclosed in the provided financial records. The valuation metrics suggest a small-cap profile, where the market capitalization of $6.89M combined with minimal revenue of $405,000 indicates that the company is currently in a pre-revenue or early-commercialization phase, relying heavily on capital markets to fund its clinical development pipeline rather than generating significant cash flow from sales.
Financial Health
The company reported a revenue of $405,000 for the trailing twelve months, yet it recorded a net income of $-9,828,000 and an EBITDA of $-9,926,000, revealing a substantial gap between top-line activity and bottom-line profitability. This discrepancy highlights a cost structure driven primarily by research and development expenses or general and administrative costs that far exceed current revenue generation. The free cash flow for the period was $-5,325,750, which signifies a significant cash burn rate that limits the company's financial flexibility and necessitates external financing to sustain operations. Margin analysis shows a gross margin of 100.0%, reflecting the absence of cost of goods sold in its current revenue model, contrasted with an operating margin of -2488.7% and a profit margin of 0.0%, which underscores the deep losses incurred before interest and taxes relative to sales. On the balance sheet, the company holds $8.54M in cash against $71,000 in debt, resulting in a debt-to-equity ratio of 1.27. Despite the reported debt, the substantial cash reserve suggests the balance sheet is not currently leveraged in a distressed manner, though the debt-to-equity figure indicates significant financial obligations relative to shareholder equity. Liquidity is supported by a current ratio of 3.46, which indicates that the company possesses ample current assets to cover its short-term liabilities without immediate refinancing needs. Return metrics are negative, with a return on equity of -178.2% and a return on assets of -66.7%, revealing that management effectiveness has not yet translated into value creation for shareholders or asset utilization, as both metrics are heavily impacted by the cumulative losses.
Valuation Assessment
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive earnings, while the forward P/E is recorded at -4.30. The negative forward P/E implies that the market is pricing in expected earnings that are still negative or that the valuation model relies on alternative assumptions given the current loss-making status. The price-to-book ratio stands at 1.47, indicating that the market is valuing the company at a 47% premium over its net book value, which may reflect potential future value in the drug pipeline rather than current assets. Alternative valuation metrics such as the price-to-sales ratio of 17.02 and an EV/EBITDA of 0.03 further suggest that the stock is priced based on intangible assets and future growth potential rather than current profitability. The stock's trading range over the last 52 weeks spans from a low of $3.12 to a high of $36.40. To determine the current price position relative to this range, one must acknowledge that the current trading price is significantly below the 52-week high of $36.40, reflecting the volatility inherent in clinical-stage biotech stocks. The beta value is listed as N/A, meaning that historical volatility data relative to the broader market is not available to assess the stock's sensitivity to market movements.
Growth & Income
Revenue growth for the year-over-year period was -43.3%, while earnings growth is listed as N/A due to the company's negative earnings history. The negative revenue growth indicates a contraction in sales, which occurs when revenue fails to keep pace with prior periods or when the company is transitioning between clinical phases. Since the company reports negative net income, there is no earnings growth to compare against revenue, and the lack of positive earnings means that earnings are not growing faster than revenue. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash is being reinvested into growth initiatives such as clinical trials and drug development rather than distributed to shareholders. The overall growth and income profile is characterized by significant financial contraction in revenue and a complete absence of dividend income, reflecting the high-risk, high-reward nature of clinical-stage biopharmaceutical development where capital is prioritized for pipeline advancement over immediate financial returns.